Adial Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, has formed a partnership with Catalent Pharma Solutions to advance clinical activities related to AD04, Adial’s genetically targeted, lead investigational new drug product for the treatment of alcohol use disorder (AUD). The partnership will allow the commencement of Adial’s planned initial Phase 3 trial, with Catalent providing packaging and distribution services.   Based on ...